share_log
Benzinga ·  Apr 23 01:15
HUTCHMED Shares Are Trading Higher After the Company Announced It Completed Enrollment of the Registration Phase of Its Phase II Trial of Savolitinib in Gastric Cancer Patients With MET Amplification
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment